|
|
ChanRx, a spin out of ChanTest, will develop small molecule drug candidates directed at ion channel targets. ChanRx will leverage the ion channel expertise resident in its parent company. Emphasis will be on repurposing drugs with prior clinical development. ChanRx has identified and completed Phase IIa clinical trials for candidate therapeutics for atrial fibrillation.
|
|
|